CPC A01K 67/0278 (2013.01) [A61K 35/51 (2013.01); A61K 49/0008 (2013.01); A01K 2207/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01)] | 19 Claims |
1. A method of determining effectiveness of a therapeutic agent targeting CD3 for treating cancer, comprising:
administering the therapeutic agent targeting CD3 to a genetically-modified, non-human mammal whose genome comprises a replacement of a nucleic acid sequence encoding all or a portion of the extracellular region of an endogenous CD3e with a nucleic acid sequence encoding the corresponding region of a human CD3e, wherein the replacement results in a sequence encoding a chimeric CD3e comprising an amino acid sequence that is at least 95% identical to amino acids 1-126 of SEQ ID NO: 7, wherein the chimeric CD3e associates with endogenous CD3γ and endogenous CD3δ, forming a functional CD3 complex on T cells in the mammal, wherein the non-human mammal detectably expresses the chimeric CD3e on the surface of one or more T cells, wherein the mammal has a cancer; and
determining the inhibitory effects of the therapeutic agent to the cancer.
|